Immunome Inc. (IMNM) PT Raised to $37 at Truist Securities, Assumes Coverage

Truist Securities analyst Supawat Thongthip raised the price target on Immunome Inc. (NASDAQ: IMNM) to $37.00 (from $36.00) while maintaining a Buy rating.

The analyst comments "We assume coverage at Buy (unchanged) and raise PT to $37 (from $36). Our valuation is anchored by varegacestat’s potential to penetrate and expand the desmoid tumor market, supported by what we view as a best-in-class ph.III efficacy and safety profile as well as convenient once-daily oral dosing. We also highlight the seasoned ex-Seagen leadership team, which we believe is well positioned to replicate prior success through next-wave ADC programs featuring novel Top1i payload/linker technology targeting ROR1 and beyond, alongside emerging radioligand therapies that collectively represent upside to our current valuation."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Berkshire adds significantly to Alphabet position, starts small position in DR Horton
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)